Indium In 111 Pentetreotide use while Breastfeeding
Medically reviewed by Drugs.com. Last updated on Mar 10, 2024.
Indium In 111 Pentetreotide Levels and Effects while Breastfeeding
Summary of Use during Lactation
Information in this record refers to the use of indium In 111 pentetreotide as a diagnostic agent. Recommendations for use in breastfeeding mothers range from no withholding of breastfeeding necessary[1] to 60 hours after a dose of 100 to 220 MBq.[2,3]
In some cases, imaging with indium In 111 pentetreotide is followed shortly by a therapy (peptide receptor radiotherapy; PRRT) that uses yttrium 90 or lutetium 177 compounds to selectively irradiate tumors. These agents may pose additional radiation risk to the nursing infant.[1]
Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level, she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[4]
Drug Levels
Indium 111 decays by electron capture with 173 keV and 245 keV gamma emissions and a physical half-life of 2.8 days.[5] The maximum effective half-life of indium In 111 pentetreotide is 10 hours.[3]
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
-
Balon HR, Brown TL, Goldsmith SJ, et al. The SNM practice guideline for somatostatin receptor scintigraphy 2.0. J Nucl Med Technol 2011;39:317-24. [PubMed: 22068564]
- 2.
-
International Atomic Energy Agency. Radiation Protection and Safety in Medical Uses of Ionizing Radiation, IAEA Safety Standards Series No. SSG-46, IAEA, Vienna. 2018. https://www
.iaea.org /publications/11102/radiation-protection-and-safety-in-medical-uses-of-ionizing-radiation - 3.
-
ARSAC notes for guidance: Good clinical practice in nuclear medicine. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. 2020. https://www
.gov.uk/government /publications /arsac-notes-for-guidance [PubMed: 10732169] - 4.
-
Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: Mechanisms, findings, and radiation dosimetry. J Nucl Med 2000;41:863-73. [PubMed: 10809203]
- 5.
-
Dilsizian V, Metter D, Palestro C, Zanzonico P. Advisory Committee on Medical Uses of Isotopes (ACMUI) Sub-Committee on Nursing Mother Guidelines for the Medical Administration of Radioactive Material. Final report submitted: January 31, 2019. 2019. https://www
.nrc.gov/docs /ML1903/ML19038A498.pdf
Substance Identification
Substance Name
Indium In 111 Pentetreotide
CAS Registry Number
139096-04-1
Drug Class
Breast Feeding
Lactation
Milk, Human
Radiopharmaceuticals
Indium Radioisotopes
Diagnostic Agents
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.